Mycoplasma genitalium has been shown to be one of the pathogens responsible for
uterine cervicitis by many studies. However, there are no clinical recommendations for treating M. genitalium-positive
uterine cervicitis. Our study retrospectively investigated the antimicrobial efficacies of several
antibiotics against
uterine cervicitis caused by M. genitalium. We studied a total of 257 women with M. genitalium-positive
uterine cervicitis, except for those with chlamydial and gonococcal
infections, who were treated with one of the following antibacterial
therapies:
azithromycin extended release formulation (AZM-SR) 2 g single dose,
azithromycin (AZM) 1 g single dose,
clarithromycin (CAM) 400 mg/day for 7 days, CAM 400 mg/day for 14 days,
moxifloxacin (MFLX) 400 mg/day for 7 days, MFLX 400 mg/day for 14 days,
levofloxacin (LVFX) 500 mg/day for 7 days, LVFX 500 mg/day for 14 days,
sitafloxacin (STFX) 200 mg/day for 7 days, and STFX 200 mg/day for 14 days. A PCR-based assay was performed to evaluate the microbiological efficacy of eradication in these patients. M. genitalium was eradicated from the uterine cervix in 19 of the 21 (90.5%) patients treated with AZM-SR 2 g single dose, in 38 of the 42 (90.5%) patients treated with MFLX 400 mg/day for 7 days, in 42 of the 42 (100%) patients treated with MFLX 400 mg/day for 14 days, and in 12 of the 13 (92.3%) patients treated with STFX 200 mg/day for 14 days. In conclusion, AZM-SR 2 g single dose, MFLX 400 mg/day for 14 days, and STFX 200 mg/day for 14 days would each be an effective treatment for M. genitalium
infection.